Ezra John Still

Title: The Innovator Behind Novel Pharmaceutical Compounds: Ezra John Still

Introduction

Ezra John Still, based in West Lafayette, Indiana, has made significant contributions to the pharmaceutical field through her innovative inventions. With a total of two patents to her name, her work focuses on developing novel compounds that aim to enhance medical treatments.

Latest Patents

One of Ezra’s latest patents is the Co-crystal compound of rivaroxaban and malonic acid. This invention relates to a novel cocrystal compound that combines rivaroxaban, a known anticoagulant, with malonic acid. The patent outlines processes for its preparation, alongside medicaments that comprise this compound, hinting at its use in controlling various diseases. Additionally, she holds a patent for 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one, also known as crystalline Form L. This patent describes methods of obtaining Form L, along with pharmaceutical compositions containing Form L and their applications in medicine.

Career Highlights

Ezra has garnered experience at prestigious companies such as Bayer Intellectual Property GmbH and Kudos Pharmaceuticals Limited. Her time at these organizations has allowed her to sharpen her skills in the realm of pharmaceutical innovation, particularly in drug development.

Collaborations

Throughout her career, Ezra has had the opportunity to work alongside talented coworkers, including Alfons Grunenberg and Karsten Fähnrich. These collaborations have contributed to her success and the advancement of her projects in drug discovery.

Conclusion

Ezra John Still stands out as an inventor dedicated to the advancement of pharmaceuticals through her patented innovations. With a focus on creating new compounds to enhance medication effectiveness, she continues to influence the field of pharmaceutical research and development. The impact of her contributions is likely to resonate in the medical community for years to come.